References

  1. W.H.O. Measles Fact Sheet. Subsequent technical references, except as noted, are from this source. Accessed 17 October 2016.

  2. Measles Rubella Initiative Accessed 17 October 2016.

  3. Centers for Disease Control and Prevention. Global measles mortality, 2000-2008. MMWR Morb Mortal Wkly Rep. 2009 Dec 4;58(47):1321-6. PubMed | Google Scholar

  4. United Nations. Demographic and Health Survey - 2014. Accessed on 2 June 2017.

  5. Sixty-third World Health Assembly. Global eradication of measles: report by the Secretariat. Geneva, Switzerland: World Health Organization, 2010. Google Scholar

  6. World Health Assembly 2012. Global Vaccine Action Plan 2011-2020. Geneva, Switzerland: World Health Organization, 2012. Accessed 24 November 2016.

  7. Strategic Advisory Group of Experts on Immunization. 2015 Assessment Report of the Global Vaccine Action Plan. Davos, Switzerland: World Health Organization, 2015. Accessed 24 November 2016.

  8. Strategic Advisory Group of Experts on Immunization. Global Vaccine Action Plan: 2016 Mid-term Review of Progress and Recommendations. Geneva, Switzerland: World Health Organization, 2016. Accessed 24 November 2016.

  9. Gastañaduy PA, Redd SB, Fiebelkorn AP, Rota JS, Rota PA, Bellini WJ, Seward JF, Wallace GS. Measles — United States, January 1–May 23, 2014. MMWR Morb Mortal Wkly Rep. 2014;63(22):496-9. PubMed | Google Scholar

  10. Measles Rubella Initiative. Measles in the African Region: Progress and Focus on Elimination 2020. Brazzaville, Republic of Congo: WHO African Regional Office, 2016. Accessed 24 November 2016.

  11. Nshimirimana D, Roungou JB. The Effort to Attain Measles Pre-elimination Targets by 2012 and to Eliminate Measles In the African Region by 2020. Brazzaville, Republic of Congo: WHO African Regional Office, 2010. Accessed 24 November 2016. Google Scholar

  12. Goodson JL, Masresha BG, Wannemuehler K, Uzicanin A, Cochi S. Changing Epidemiology of Measles in Africa. Journal of Infectious Diseases. 2011;204(suppl 1):S205-S14. PubMed | Google Scholar

  13. WHO Media Center. WHO warns that progress towards eliminating measles has stalled. Geneva, Switzerland: World Health Organization, 2014. Accessed 24 November 2016.

  14. Centers for Disease Control and Prevention. Progress in Measles Control - Kenya 2002-2007. MMWR Morb Mortal Wkly Rep. 2007;56(37):969-972. PubMed | Google Scholar

  15. Centers for Disease Control and Prevention. Measles — Horn of Africa, 2010–2011. MMWR Morb Mortal Wkly Rep. 2012;61(34):678-684. PubMed | Google Scholar

  16. WHO vaccine-preventable diseases: monitoring system. 2016 global summary. Geneva, Switzerland: World Health Organization, 2016. Accessed 24 November 2016.

  17. WHO AFRO. Kenya Rolls out massive Measles-Rubella and Tetanus campaign. 2016 May. Accessed 17 October 2016.

  18. W.H.O. Open-vials policy reports. Geneva, Switzerland: World Health Organization. Accessed 2 December 2016.

  19. Shen AK, Fields R, McQuestion M. The future of routine immunization in the developing world: challenges and opportunities. Glob Health Sci Pract. 2014;2(4):381-394. PubMed | Google Scholar

  20. Hutin Y, Hauri AM, Armstrong GL. Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates. British Medical Journal. 2003;327:1075. PubMed | Google Scholar

  21. World Health Organization. Safety of injection, WHO-UNICEF policy statement for mass campaigns. Wkly Epidemiol Rec. 1998 Dec 11;73(50):394-6. PubMed | Google Scholar

  22. Hoekstra EJ, van den Ent MMVX, Dao H, Khalaf H, Salovaara A. Measles Supplementary Immunization Activities and GAVI Funds as Catalysts for Improving Injection Safety in Africa. J Infect Dis. 2011;204(suppl 1):S190-S197. PubMed | Google Scholar

  23. Sabin AB, Arechiga AF, de Castro JF, Sever JL, Madden DL, Shekarchi I, Albrecht P. Successful Immunization of Children With and Without Maternal Antibody by Aerosolized Measles Vaccine: I Different Results With Undiluted Human Diploid Cell and Chick Embryo Fibroblast Vaccines. JAMA. 1983;249(19):2651-2662. PubMed | Google Scholar

  24. Low N, Kraemer S, Schneider M, Restrepo AM. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine. 2008 Jan;26(3):383-98. PubMed | Google Scholar

  25. Low N, Bavdekar A, Jeyaseelan L et al. A Randomized, Controlled Trial of an Aerosolized Vaccine against Measles. New England Journal of Medicine. 2015;372(16):1519-29. PubMed | Google Scholar

  26. CDC, WHO. History and Epidemiology of Global Smallpox Eradication. From the training course titled Smallpox: Disease, Prevention, and Intervention. Slide 16-17. Accessed 24 November 2016.

  27. WHO. Measles vaccines: WHO position paper. Weekly epidemiological record. 2009 Aug;84(35):349-60. PubMed | Google Scholar

  28. Module 7: measles update 2009. Geneva, World Health Organization, 2009 (The Immunological basis for immunization series). Accessed 2 june 2017.

  29. Kenya Ministry of Health. Measles vaccine second dose introduction in routine immunization: A Guide for Health Workers. MOH, Division of Vaccines and Immunization. 2013 Jul. Accessed 30 October 2016.

  30. Turner N. Global Status of MCV2: Time to remove the introduction criterion? Geneva, Switzerland: SAGE Working Group on Measles & Rubella, 2016 Aug. Accessed 30 October 2016.

  31. Bartlett MS. Measles periodicity and community size. J Roy Stat Soc Ser. A 1957;120:48-70. Google Scholar

  32. WHO. Measles vaccines: WHO position paper. Weekly epidemiological record. 2009 Aug;84(35):349-60. PubMed | Google Scholar

  33. Kamadjeu R. MCV2 Introduction and the Second Year of Life Contact: Lessons and Way Forward. Meeting of the WHO AFRO Measles and Rubella Technical Advisory Group. Nairobi, Kenya: UNICEF ESARO, 2015. PubMed | Google Scholar

  34. WHO. Measles vaccines: WHO position paper. Weekly epidemiological record. 2009 Aug;84(35):349-60. PubMed | Google Scholar

  35. WHO. Kenya: WHO and UNICEF estimates of immunization coverage: 2015 revision. Accessed 25 November 2016.

  36. WHO. Global routine vaccination coverage, 2013. Weekly epidemiological record. 2014;89:517-528 47. PubMed | Google Scholar

  37. Makokha FM, Wanjala PM, Githuku J, Kutima HL. Uptake of Second Dose of Measles-Containing Vaccine among Children in Kakamega County, Kenya. International Journal of Scientific and Research Publications. 2015 Jul;5(7):1-4. PubMed | Google Scholar

  38. Measles & Rubella Initiative. Field Manual for House-to-House Social Mobilization for Measles and Measles/Rubella Supplemental Immunization Activities (SIA) and Routine Immunization. D.C., USA: American Red Cross, 2016. PubMed | Google Scholar

  39. Measles Rubella Initiative. House to House Mobilization to Raise Caregivers’ Knowledge Before and During Measles and MR SIAs. D.C., USA: American Red Cross, 2016. Unpublished Data. Google Scholar

  40. African Regional Measles & Rubella Technical Advisory Group. Status of implementation of recommendations from the 4th African Regional Measles & Rubella TAG Meeting. Nairobi, Kenya: World Health Organization Regional Office for Africa, 2015 Jun. Google Scholar

  41. Measles & Rubella Initiative. Field Manual for House-to-House Social Mobilization for Measles and Measles/Rubella Supplemental Immunization Activities (SIA) and Routine Immunization. D.C., USA: American Red Cross, 2016. PubMed | Google Scholar

  42. Measles Rubella Initiative. House to House Mobilization to Raise Caregivers’ Knowledge Before and During Measles and MR SIAs. D.C., USA: American Red Cross, 2016. Unpublished Data. Google Scholar

  43. GAVI News. Lions Clubs mobilise for World Immunization Week. Geneva, Switzerland: Global Alliance for Vaccines and Immunization. Accessed 29 November 2016.

  44. Mbabazi WB, Collins TW, Chemirmir C et al. Innovations in communication technologies for measles supplemental immunization activities: lessons from Kenya measles vaccination campaign, November 2012. Health Policy Plan. 2015 Jun;30(5):638-44. PubMed | Google Scholar

  45. DREF Operation. Kenya: Measles Outbreak. DREF Operation no. MDRKE017. International Federation of Red Cross and Red Crescent Society. 2011. Google Scholar

  46. WHO Regional Office for Africa. African Regional Guidelines for Measles and Rubella Surveillance. Congo-Brazaville: WHO AFRO; 2015. Google Scholar

  47. Centers for Disease Control and Prevention. Progress in Measles Control - Kenya 2002-2007. MMWR Morb Mortal Wkly Rep. 2007;56(37):969-972. PubMed | Google Scholar

  48. DREF Operation. Kenya: Measles Outbreak. International Federation of Red Cross and Red Crescent Society. DREF Operation no. MDRKE017. 2011 Apr. PubMed | Google Scholar

  49. DREF Operation. DREF Final Report, Kenya: Measles Outbreak. International Federation of Red Cross and Red Crescent Society. DREF Operation no. MDRKE017. 2011 Apr. PubMed | Google Scholar

  50. Enquselassie F, Ayele W, Dejene A et al. Seroepidemiology of measles in Addis Ababa, Ethiopia: implications for control through vaccination. Epidemiol Infect. 2003 Jun;130(3):507-19. Google Scholar

  51. Cutts FT, Hanson M. Seroepidemiology: an underused tool for designing and monitoring vaccination programmes in low- and middle-income countries. Trop Med Int Health. 2016 Sep;21(9):1086-98. PubMed | Google Scholar

  52. Ohuma EO, Okiro EA, Bett A et al. Evaluation of a measles vaccine campaign by oral-fluid surveys in a rural Kenyan district: interpretation of antibody prevalence data using mixture models. Epidemiol Infect. 2009 Feb;137(2):227-33. PubMed | Google Scholar

  53. WHO WPRO. Fourth Meeting on Vaccine Preventable Diseases Laboratory Networks in the Western Pacific Region. Manila, Philippines: World Health Organization Western Pacific Region, 2013. Accessed 27 November 2016.

  54. Mbugua FM, Okoth FA, Gray M et al. Molecular epidemiology of measles virus in Kenya. J Med Virol. 2003 Dec;71(4):599-604. PubMed | Google Scholar

  55. Kutty P, Rota J, Bellini W et al. Manual for the Surveillance of Vaccine-Preventable Diseases, Chapter 7: Measles. Georgia, USA: Center for Disease Control and Prevention, 2014. Accessed 27 November 2016.

  56. W.H.O. Manual for the diagnosis of measles and rubella infection, 2nd edn. Geneva, Switzerland, World Health Organization, 2007. Accessed 27 November 2016.

  57. Kombich JJ, Muchai PC, Tukei P, Borus PK. Rubella seroprevalence among primary and pre- primary school pupils at Moi's Bridge location, Uasin Gishu District, Kenya. BMC Public Health. 2009;9(1):269. Google Scholar

  58. Jacobson Vann JC, Szilagyi P. Patient reminder and recall systems to improve immunization rates. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003941. PubMed | Google Scholar

  59. Wakadha H, Chandir S, Were EV et al. The feasibility of using mobile-phone based SMS reminders and conditional cash transfers to improve timely immunization in rural Kenya. Vaccine. 2013 Jan;31(6):987-993. PubMed | Google Scholar

  60. Haji A, Lowther S, Ngan’ga Z et al. Reducing routine vaccination dropout rates: evaluating two interventions in three Kenyan districts, 2014. BMC Public Health. 2016;16(1):152. PubMed | Google Scholar

  61. Gibson D et al. Personal Communications: Email Correspondence - Based on protocol paper: The Mobile Solutions for Immunization (M-SIMU) Trial: A Protocol for a Cluster Randomized Controlled Trial That Assesses the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya. 2016 May 17;5(2): e72. Google Scholar

  62. Edens C, Collins ML, Ayers J, Rota PA, Prausnitz MR. Measles vaccination using a microneedle patch. Vaccine. 2013 Jul;31(34):3403-9. PubMed | Google Scholar

  63. Edens C, Collins ML, Goodson JL, Rota PA, Prausnitz MR. A microneedle patch containing measles vaccine is immunogenic in non-human primates. Vaccine. 2015 Sep;33(37):4712-8. PubMed | Google Scholar

  64. Arya J, Prausnitz MR. Microneedle patches for vaccination in developing countries. J Control Release. 2016 Oct 28;240:135-141. PubMed | Google Scholar